Evidence map›Paper›PMID 41341749›Full record

ArticleMolecular therapy. Nucleic acids2025

Loop engineering improves prime editing efficiency.

Bailun Li, Zhike Lu, Ting Zhou, Huilin Mou, Zhilin Zou, Keyi Yao, Zhenxing Yu, Wenyu Ma, Tingliang Wang, Miao He and 1 more

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bailun LiCollege of Life Sciences, Zhejiang University, Hangzhou 310058, China.
Zhike LuSchool of Life Sciences, Westlake University, Hangzhou 310030, China.
Ting ZhouCollege of Life Sciences, Zhejiang University, Hangzhou 310058, China.
Huilin MouSchool of Life Sciences, Westlake University, Hangzhou 310030, China.
Zhilin ZouSchool of Life Sciences, Westlake University, Hangzhou 310030, China.
Keyi YaoSchool of Life Sciences, Westlake University, Hangzhou 310030, China.
Zhenxing YuSchool of Life Sciences, Westlake University, Hangzhou 310030, China.
Wenyu MaSchool of Life Sciences, Westlake University, Hangzhou 310030, China.
Tingliang WangSchool of Life Sciences, Westlake University, Hangzhou 310030, China.
Miao HeCenter for Evolutionary & Organismal Biology, Zhejiang University School of Medicine, Hangzhou 310058, China.
Lijia MaSchool of Life Sciences, Westlake University, Hangzhou 310030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prime editor (PE) offers significant translational potential due to its diverse editing outcomes. However, its editing efficiency is generally lower than that of wild-type Cas9 and base editor (BE). Previous investigations have suggested that the availability of the primer binding site (PBS) and reverse transcription template (RTT) within the pegRNA limits the installation of desired edits at target sites. In this study, we investigated whether the position and copy number of PBS-RTT sequences are important parameters influencing PE editing efficiencies. We inserted extra copies of the PBS-RTT sequence into the loop 2, tetraloop, or the 3' end of pegRNA, as well as moved the 3' PBS-RTT to the internal stem-loops of sgRNA. Incorporating an extra PBS-RTT copy into loop 2, but not tetraloop, increased PE editing efficiency by 40%-147% across various target sites and cellular contexts. This suggests that both the local concentration and steric hindrance of the PBS-RTT sequence appear to affect its accessibility to the DNA nicking end, ultimately influencing the editing efficiency of PE. By addressing the bottleneck of limited PBS-RTT availability, our strategy may broaden the wide applicability of PE, especially in translational medicine.

Indexed as

local concentrationMT: RNA/DNA EditingPBS-RTTpegRNAprime editingsteric hindrance

Identifiers

PMID41341749
PMCPMC12670555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.